Uveitis Prompts Partial Clinical Hold on Nuvation Bio Cancer Drug

Uveitis — an inflammation of the middle layer of the eye — in treated patients has prompted FDA to halt enrollment in Nuvation Bio’s phase 1/2 dose-escalation study of NUV-422, a checkpoint inhibitor under investigation for a wide variety of solid tumors.
Source: Drug Industry Daily